Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclonal antibody derived from a non-human source.
Rebecca L BrocatoHua WuSteven A KwilasLucia M PrincipeMatthew JosleynJoshua ShamblinPadmanabh ChivukulaChristoph BauschThomas LukeEddie J SullivanJay W HooperPublished in: mBio (2024)
This candidate polyclonal human IgG product was produced using synthetic gene-based vaccines and transgenic cows. Having now gone through cGMP production, GLP safety testing, and efficacy testing in animals, SAB-163 is the world's most advanced anti-hantavirus antibody-based medical countermeasure, aside from convalescent human plasma. Importantly, SAB-163 targets the most prevalent hantaviruses on four continents.